Sterol regulatory element binding protein (SREBP) is an important potential mediator of kidney fibrosis and is known to be upregulated in diabetic nephropathy. We evaluated the effectiveness of SREBP inhibition as treatment of diabetic nephropathy. Type 1 diabetes was induced in uninephrectomized male CD1 mice with streptozotocin. The mice were treated with the SREBP inhibitor fatostatin for 12 weeks. At the endpoint, kidney function and pathologic findings were assessed. Fatostatin inhibited the increase of both isoforms of SREBP (types 1 and 2) in diabetic kidneys. Treatment attenuated basement membrane thickening but did not improve hyperfiltration, albuminuria, or kidney fibrosis in diabetic mice. The treatment of nondiabetic mice with fatostatin led to hyperfiltration and increased the glomerular volume to levels seen in diabetic mice. This was associated with increased renal inflammation and a trend toward increased renal fibrosis. Both in vivo and in cultured renal proximal tubular epithelial cells, fatostatin increased the expression of the proinflammatory cytokine monocyte chemoattractant protein-1. Thus, SREBP inhibition with fatostatin not only is ineffective in preventing diabetic nephropathy but also leads to kidney injury in nondiabetic mice. Further research on the efficacy of other SREBP inhibitors and the specific roles of SREBP-1 and SREBP-2 in the treatment and pathogenesis of diabetic nephropathy is needed. (Endocrinology 159: 1479(Endocrinology 159: -1495(Endocrinology 159: , 2018 D iabetic nephropathy (DN) is the leading cause of end-stage renal disease and is characterized by the accumulation of extracellular matrix proteins (ECMs) in the glomerulus and, in later stages, in the tubulointerstitial space (1). Current therapy, comprising glycemic control, blood pressure regulation, and the use of inhibitors of angiotensin II signaling, is only capable of slowing the progression of DN (2). Thus, better understanding of the mechanisms leading to the development and progression of DN is important to the identification of new treatment strategies.
D
iabetic nephropathy (DN) is the leading cause of end-stage renal disease and is characterized by the accumulation of extracellular matrix proteins (ECMs) in the glomerulus and, in later stages, in the tubulointerstitial space (1) . Current therapy, comprising glycemic control, blood pressure regulation, and the use of inhibitors of angiotensin II signaling, is only capable of slowing the progression of DN (2) . Thus, better understanding of the mechanisms leading to the development and progression of DN is important to the identification of new treatment strategies.
Sterol regulatory element binding proteins (SREBPs) are members of the basic helix-loop-helix leucine zipper family of transcription factors that primarily regulate fatty acid and cholesterol levels (3, 4) . We have also, however, demonstrated an additional direct, lipid-independent role for SREBP-1 in promoting signaling by the profibrotic cytokine transforming growth factor-b (TGF-b) 1 in kidney glomerular mesangial cells (5) (6) (7) . SREBPs are retained in the endoplasmic reticulum as large transcriptionally inactive precursors through interaction with SREBP cleavageactivated protein (SCAP) and insulin-induced gene 1. In response to sterol-deficient conditions, the interaction between insulin-induced gene 1 and SCAP is disrupted, leading to translocation of the SREBP-SCAP complex to the Golgi. Within the Golgi, SREBP is cleaved by membrane-associated site 1 and site 2 proteases to form the transcriptionally active fragment, which then translocates to the nucleus to affect signaling (8) .
Renal expression of SREBP-1 is increased in models of both type 1 and type 2 diabetes (8) (9) (10) (11) (12) . SREBP-1 gene transcription uses alternative start sites, which leads to the expression of two isoforms, SREBP-1a and SREBP1c. SREBP-1a is a potent regulator of cholesterol metabolism and is the predominant isoform in cell culture (4) . SREBP-1c preferentially regulates fatty acid synthesis and is the predominant isoform in most tissues (4) . Renal overexpression of SREBP-1a led to albuminuria and glomerulosclerosis reminiscent of DN, and very early DN (assessed by albuminuria) was inhibited in type 1 diabetic SREBP-1c knockout mice (8, 11) . These studies suggest an important role for SREBP-1 in the progression of DN. Although no such role has as yet been found for the third isoform, SREBP-2, its expression was also found to be increased in diabetic kidneys (12, 13) .
We previously demonstrated that the nonspecific SREBP inhibitor fatostatin, which inhibits both SREBP1a/1c and SREBP-2, attenuated renal fibrosis and improved renal function in a hypertensive model of kidney disease induced by angiotensin II infusion (14) . Fatostatin also attenuated kidney interstitial fibrosis in the unilateral ureteral obstruction model (15) . Whether fatostatin could prevent or delay the development of DN has not yet been examined and was the focus of the present study.
Materials and Methods

Animal studies
Animal studies were performed in accordance with Canadian Council on Animal Care guidelines, with approval of the protocol by the animal research ethics board at McMaster University. Male CD1 mice (Charles River Laboratories, Sherbrooke, QC, Canada), aged 9 weeks, underwent left nephrectomy. At 10 weeks of age, diabetes was induced by a single intraperitoneal injection of streptozotocin at 200 mg/kg. Control mice were injected with an equal volume of citrate buffer. Blood glucose was tested the following week, and mice with values .17 mM were enrolled in the present study. Diabetic mice that developed ketonuria (assessed by dipstick; Bayer Multistix, Toronto, ON, Canada) were implanted with an insulin pellet (LinShin Canada, Toronto, ON, Canada) to maintain the body weight but not correct hyperglycemia. All diabetic mice required insulin implantation. Male type 1 diabetic Akita mice (Ins2
; Akita/+) and wild-type littermates (WT; Ins2 +/+ ) were also used. The mice were administered fatostatin (30 mg/kg) or vehicle (7.5% dimethyl sulfoxide in saline) intraperitoneally daily after confirmation of hyperglycemia in the CD1 mice and at 36 weeks of age in the Akita mice. This dose was previously shown to effectively inhibit SREBP-1 and SREBP-2 activity in vivo in mice (14, 15) . In the CD1 groups, 6 mice each were in the nondiabetic vehicle and fatostatin-treated groups, with 12 mice each in the diabetic vehicle and fatostatin-treated groups. The CD1 mice were euthanized 12 weeks after the induction of diabetes. For the Akita mice, 4 mice each were included in the groups: wildtype, Akita, and fatostatin-treated Akita mice at 36 weeks of age. The Akita mice were euthanized at 40 weeks of age. At the end of the study, urine was collected, blood pressure was assessed by tail cuff plethysmography (CODA 2 system; Kent Scientific, Torrington, CT), and the glomerular filtration rate (GFR) was assessed as described in the next section. Urine 8-hydroxy2
0 -deoxyguanosine (8-OHdG; STA320; Cell Bio Laboratories, San Diego, CA), creatinine (80350; Crystal Chem, Elk Grove Village, IL), and albumin (1011; Exocell, Philadelphia, PA) were measured using the appropriate kit.
Glomerular filtration rate
GFR was assessed by clearance of fluorescein isothiocyanatelabeled sinistrin (Fresenius Kabi, Linz, Austria). A 5% fluorescein isothiocyanate-sinistrin solution in saline was injected retro-orbitally. Blood was collected into heparinized test tubes from the saphenous vein at 3, 7, 10, 15, 35, 55, and 75 minutes after injection. Plasma fluorescence was assessed using a fluorometer (Gemini EM; Molecular Devices, San Jose, CA) at 485 nm excitation and 538 nm emission.
Imaging
Formalin-fixed sections (4 mm) were stained with periodic acid-Schiff (PAS) reagent, trichrome (Sigma-Aldrich, St. Louis, MO), or picrosirius red (Polyscience Inc., Warrington, PA). Glomerular hypertrophy was assessed by measuring the glomerular cross-sectional area [G(A)] of 40 glomeruli per mouse. The glomerular volume was estimated using the formula V(G) = 1.38/1.10 3 [G(A)] 3/2 (17) . Glomerular fibrosis was scored semiquantitatively by one of us (A.J.I.) in a blinded fashion on 10 glomeruli per mouse (0, none; 1+, #25%; +2, 25% to 50%; +3, $50% of glomerular area affected). Picrosirius red-stained tissue was visualized under polarized light to highlight areas of collagen accumulation. Corresponding images were also taken under normal light to demonstrate the pathologic features of the surrounding tissue. Picrosirius red and trichrome staining were assessed by measuring the percentage of positive area using ImageJ (National Institutes of Health, Bethesda, MD). For immunohistochemistry (IHC), the sections were deparaffinized and exposed to heat-induced epitope retrieval for staining with SREBP-1 (Abcam, Toronto, ON, Canada), SREBP-2 (Santa Cruz, Dallas, TX), a-smooth muscle actin (a-SMA; Thermo Fisher Scientific, Burlington, ON, Canada), monocyte chemoattractant protein-1 (MCP-1; Biolegend, San Diego, CA), and CD3 (Dako, Burlington, ON, Canada). Staining with type I TGF-b receptor (TbRI; Santa Cruz) was conducted without antigen retrieval. F4/80 staining was performed by the McMaster University core histology laboratory. Negative controls were included using primary or secondary antibodies alone; a select sample is shown in Supplemental Fig. 1 . Images were taken at 3200 and 3400 magnification, with staining quantified as above. Electron microscopy (EM) was performed on a small piece of kidney cortex fixed in 0.2 M glutaraldehyde (pH 7.4) and 0.1 M sodium cacodylate and processed by the McMaster University EM facility. The basement membrane thickness was assessed on glomerular peripheral loops at 312,500 magnification through calculation of the harmonic mean of 100 randomly selected points.
Nanostring analysis
Messenger RNA (mRNA) was isolated from kidney tissue using Trizol (Invitrogen, Carlsbad, CA) and sent for analysis using nCounter (NanoString Technologies, Seattle, WA) at the Farncombe Metagenomics Facility at McMaster University. Data were analyzed using nSolver, version 2.5, provided by the manufacturer (NanoString Technologies). Samples were normalized using background subtraction with the negative control and the geometric mean of the positive control and the housekeeping gene b-actin (ACTB).
Protein analysis
Protein from the renal cortex was extracted as previously reported (18) . In brief, tissue was sonicated in lysis buffer. Lysate was centrifuged for 10 minutes at 13,000 rpm to clear debris. The supernatant was separated on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel for subsequent immunoblotting. Antibodies against phosphorylated Smad3 (pSmad3; 1:3000; Millipore, Burlington, MA), a-SMA (1:10,000; Thermo Fisher Scientific), tubulin (1:10,000; SigmaAldrich), MCP-1 (1:1000; Biolegend or Dako), and cleaved caspase 3 (1:500; Cell Signaling, Danvers, MA) were used. Protein expression was normalized to tubulin.
Cell culture
Primary mesangial cells were isolated from male SpragueDawley rats as previously reported (5) . Mesangial cells were cultured in Dulbecco's modified Eagle medium supplemented with 20% fetal bovine serum, streptomycin (100 mg/mL), and penicillin (100 mg/mL). Cells between passages 8 and 17 were used. Human proximal tubular epithelial HK2 cells were cultured in a low-glucose Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, streptomycin (100 mg/mL), and penicillin (100 mg/mL). All cells were kept at 37°C in 95% air, 5% carbon dioxide. The cells were serum deprived at 80% to 90% confluence overnight and then treated for 24 hours with fatostatin [20 mM, previously shown to inhibit SREBP-1 and SREBP-2 activity (16, 19) ].
mRNA analysis mRNA was isolated using Trizol (Invitrogen), with 1 mg reverse transcribed using qScript (Quanta Biosciences, Beverly, MA). Real-time polymerase chain reaction was performed using primers for mouse SREBP-1 (forward:
, and human ACTB (forward: 5 0 -ACCGAG-CGCGGCTACAG-3 0 ; reverse: 5 0 -CTTAATGTCACGCACGA-TTTCC-3 0 ). Reactions were performed using a 7600 system (Applied Biosystems, Foster City, CA). mRNA was determined relative to 18S (for rat samples) or ACTB (for human samples) using the DD C T method.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (version 5.0; GraphPad Software, Inc., San Diego, CA) with one-way analysis of variance with Tukey honest significant difference for post hoc analysis. Survival curve analysis was conducted using a log-rank (Mantel-Cox) test. Analysis of the data with two groups was performed using the Student t test. P , 0.05 was considered significant. Data are presented as the mean 6 standard error of the mean.
Results
Fatostatin inhibits SREBP-1 and SREBP-2 in vivo
After 12 weeks of hyperglycemia, the mice were assessed for the development of DN. The clinical characteristics of the mice are presented in Table 1 . Diabetic CD1 mice injected with both vehicle and fatostatin all required insulin pellet implantation to prevent ketonuria and maintain hyperglycemia, as outlined in the Methods and Materials section. The blood glucose of the diabetic mice was beyond the measurement range of the glucometer and was thus recorded as .27.0 mM. Fatostatin significantly reduced blood glucose in nondiabetic mice, consistent with reports that identified SREBP-1c as an important determinant in hepatic glucose regulation (19, 20) . The systolic and diastolic blood pressure in both diabetic groups were significantly increased compared with both nondiabetic groups. Fatostatin did not significantly affect blood pressure in diabetic or nondiabetic mice. The diabetic mice weighed significantly less than did the untreated nondiabetic mice. Fatostatin did not affect the weight of the diabetic mice but attenuated the weight gain in the nondiabetic mice. A similar decrease in weight was seen in obese db/db mice treated with fatostatin (21) . Renal hypertrophy, as assessed by the kidney-to-body weight ratio, was significantly increased in the diabetic mice treated with vehicle and fatostatin compared with that in the nondiabetic mice. However, Control (n = 6) Fatostatin (n = 6) Control (n = 7) Fatostatin (n = 7)
Blood glucose (mM) 9.5 6 0. renal hypertrophy was not significantly affected by fatostatin in the diabetic mice. Fatostatin is a potent inhibitor of SREBP-1 and SREBP-2 activation through its inhibition of SCAP (20) . To assess the efficacy of fatostatin in our model system, we first determined the protein expression of SREBP. Both SREBP-1 and SREBP-2 were increased in diabetic kidneys as assessed by IHC ( Fig. 1A and 1B) and as seen by others in various models of type 1 DN (8) (9) (10) (11) (12) . Fatostatin prevented this. The lack of attenuation of basal levels of either isoform likely resulted from their low level of expression in normal kidneys. Both SREBP-1 and SREBP-2 induce their own transcriptional expression through sterol regulatory element sites, with fatostatin thereby attenuating the expression of the precursor transcripts and proteins (21) . As expected, renal transcript expression of both isoforms was also inhibited by fatostatin ( Fig. 1C and 1D ), although we did not observe upregulation in these transcripts with diabetes.
Fatostatin does not improve renal function or albuminuria in diabetic mice
As shown in Fig. 2A , a significant increase in mortality occurred after the induction of diabetes that was unaffected by treatment with fatostatin. Similar mortality rates of CD1 diabetic mice have been demonstrated by others (22, 23) . Albuminuria, a major hallmark of DN, was significantly elevated in the diabetic mice but was not affected by treatment with fatostatin (Fig. 2B) . Increased thickening of the glomerular basement membrane, another characteristic feature of diabetic kidney disease, was assessed by EM. Interestingly, fatostatin prevented basement membrane thickening in diabetic mice (Fig. 2C) .
Early DN is characterized by hyperfiltration, manifesting as an elevated GFR. As shown in Fig. 2D , diabetic mice developed significant hyperfiltration, but this was not affected by fatostatin. However, fatostatin significantly increased the GFR in nondiabetic mice. Glomerular hypertrophy, also seen in early DN, was assessed by estimating the volume of glomeruli as described in the Methods and Materials section. The diabetic mice developed glomerular hypertrophy and this was not affected by fatostatin (Fig. 2E) . Similar to its effects on the GFR, fatostatin induced glomerular hypertrophy in nondiabetic mice.
Fatostatin does not attenuate renal fibrosis or profibrotic signaling in diabetic kidneys
Glomerulosclerosis and, in advanced disease, tubulointerstitial fibrosis are hallmark pathologic features of DN (24) . Diabetic mice developed both glomerulosclerosis and tubulointerstitial fibrosis, as assessed by PAS reagent and trichrome staining, respectively. Neither was affected by fatostatin ( Fig. 3A and 3B ). Deposition of collagen was further assessed by staining with picrosirius red. This was increased in diabetic mice but was unaffected by fatostatin (Fig. 3C) . Corresponding to the increased collagen deposition, mRNA expression of collagens I, III, and IV showed a trend toward an increase in diabetic kidneys without attenuation by fatostatin The urine albumin/creatinine ratio was elevated in diabetic mice but was not affected by treatment with fatostatin (n = 6 per group). (C) Fatostatin reduced basement membrane thickening in diabetic mice (n = 4 for control groups; n = 6 for diabetic groups). (D) Fatostatin did not decrease the elevated GFR in diabetic mice and increased the GFR in control mice (n = 5 per group). (E) Fatostatin did not improve glomerular hypertrophy in diabetic mice, and promoted glomerular hypertrophy in nondiabetic mice (n = 6 per group). *P , 0.05. Con, control; DM, diabetes; Fato, fatostatin. ( Fig. 3D) . Fibronectin expression was also increased in diabetic mice, without inhibition by fatostatin (Fig. 3E) . Rather, fatostatin increased fibronectin transcript and protein in nondiabetic mice (Fig. 3D and 3E) . Elevated expression of a-SMA is a marker of activated renal myofibroblasts (25) and is associated with tubulointerstitial fibrosis. Expression of a-SMA was significantly increased in the nondiabetic and diabetic mice treated with fatostatin, as assessed by immunoblotting and IHC ( Fig. 3F and 3G, respectively) .
TGF-b1 has been identified as a key mediator of renal fibrosis in DN through activation of its downstream mediator Smad3 (26) . Renal mRNA expression of TGFb1 was elevated in diabetic mice, with expression unaffected by fatostatin (Fig. 4A) . pSmad3, indicative of Smad3 activation, was elevated in diabetic mice and was also unaffected by fatostatin (Fig. 4B) . A nonsignificant increase was found in TGF-b1 and pSmad3 expression in nondiabetic mice given fatostatin. We previously reported that treatment with fatostatin reduced expression of TbRI in mesangial cells exposed to high glucose (7). Expression of TbRI was also seen to be significantly reduced in diabetic mice treated with fatostatin (Fig. 4C) . However, this decrease was insufficient to attenuate TGF-b signaling.
Fatostatin promotes renal inflammation
Renal inflammation is a major contributor to the pathogenesis of DN and is characterized by recruitment of macrophages and T cells (27) . SREBPs have been suggested to play a critical role in the inflammatory response through regulation of inflammatory cytokines and facilitation of clonal expansion (28) (29) (30) .
Elevated mRNA expression of the chemokines MCP-1, RANTES, and tumor necrosis factor-a and the T-cell marker CD3 and macrophage marker F4/80 were seen in diabetic kidneys. F4/80, MCP-1, and RANTES were significantly upregulated in diabetic mice compared with nondiabetic mice by t test only. Fatostatin did not significantly affect their expression in diabetic mice but tended to increase their expression in nondiabetic kidneys (Fig. 5A ).
The accumulation of T cells in diabetic kidneys and in fatostatin-treated nondiabetic mice was also demonstrated using IHC (Fig. 5B) and immunoblotting (Fig. 5C) . Furthermore, treatment with fatostatin did not attenuate macrophage accumulation in diabetic kidneys but tended to increase this in both nondiabetic and diabetic kidneys, as assessed by IHC (Fig. 5D) . Overexpression of SREBP-1a, SREBP-1c, and SREBP-2 in mice has been associated with decreased accumulation of arachidonic acid in the liver (31, 32). Arachidonic acid is a precursor for a number of bioactive lipids that have been implicated in regulating inflammation and renal blood flow (33) . Fatostatin did not significantly alter the amount of arachidonic acid in the kidney of nondiabetic or diabetic mice (data not shown).
MCP-1 is a chemokine that regulates the trafficking and recruitment of macrophages and is secreted by both mesangial cells and tubular cells (34) . Fatostatin did not inhibit MCP-1 upregulation in diabetic kidneys. Rather, treatment of nondiabetic mice with fatostatin led to increased MCP-1 expression to levels similar to that in diabetic mice, as assessed by immunoblotting and IHC Figure 4 . Fatostatin did not attenuate TGF-b1 upregulation and signaling. (A) Upregulation of TGF-b1 transcript levels by diabetes (DM) was not inhibited by fatostatin (n = 4 per group) as assessed by nanostring. (B) Smad3 activation, assessed by its C-terminus phosphorylation, was increased in diabetic kidneys. Fatostatin did not inhibit this (n = 6 per group). (C) Expression of TbRI was significantly decreased by treatment with fatostatin in diabetic kidneys, which corresponded with our previous study (n = 3 per group). *P , 0.05. Con, control; Fato, fatostatin.
( Fig. 6A and 6B, respectively) . In vitro, treatment of primary mesangial cells with fatostatin led to decreased mRNA expression of MCP-1 (Fig. 6C) . However, treatment of proximal tubular HK2 cells increased the MCP-1 transcript under normo-and hyperglycemic conditions (Fig. 6D) and increased protein expression in hyperglycemia (Fig. 6E ). This suggests that an effect of fatostatin on renal tubular cells might be responsible for driving inflammation in our model. Transcript expression of inflammatory cell markers and proinflammatory cytokines was assessed by nanostring analysis. These were increased in diabetic kidneys but not attenuated by fatostatin, which also increased their expression in nondiabetic kidneys (n = 6 per group). The increase in diabetic vs nondiabetic kidneys was significant (t test). (B and C) T-cell infiltration was assessed by (B) IHC and (C) immunoblotting for CD3 (n = 6 per group). CD3 expression was increased in diabetic mice. Fatostatin augmented CD3 presence in both diabetic and nondiabetic kidneys. (D) Macrophage infiltration was assessed by IHC for F4/80. F4/80 staining was increased in diabetic kidneys and was not attenuated by fatostatin [n = 6 per control (Con) groups; n = 3 per diabetic groups]. A trend was seen toward an increase in both diabetic and nondiabetic mice treated with fatostatin. *P , 0.05 (analysis of variance); Fatostatin does not inhibit renal oxidative stress or apoptosis Renal oxidative stress has been implicated in the development of diabetic microvascular complications, including DN (35) . The reduced form of nicotinamide adenine dinucleotide phosphate oxidase (NOX) is known to be a major contributing source of reactive oxidative species in diabetic kidneys, with NOX-2 an important inducible component of this enzyme complex (36) . Expression of the NOX-2 transcript was elevated in diabetic mice but was not altered by fatostatin (Fig. 7A) . A trend was seen toward increased expression of NOX-2 in nondiabetic mice treated with fatostatin. No significant difference was seen in the expression of the NOX-4 transcript in any of the groups (data not shown). Associated with the increased Nox2 expression, an increase was seen in oxidative stress in diabetic kidneys as measured by urinary 8-OHdG, which was unaffected by fatostatin (Fig. 7B) . A trend was seen toward increased urinary 8-OHdG in nondiabetic mice treated with fatostatin.
Through loss of renal glomerular and tubular cells, apoptosis has been identified as an important process by which early DN develops (37) . Proteolytic cleavage of caspase 3 is associated with activation of apoptotic signaling (38) and has been used as an indicator of apoptosis. Cleaved caspase 3 was not observed in either of the control groups. This was, however, clearly seen in diabetic mice and significantly increased by treatment with fatostatin in mice with diabetes (Fig. 7C) .
Fatostatin does not improve nephropathy in type 1 diabetic Akita mice
To determine whether fatostatin has similar effects in another model of DN, we treated 36-week-old Akita mice, a time at which time DN is established in this model (39) (40) (41) (42) . The mice were treated for 1 month, with the pathologic features and renal function assessed at 40 weeks of age.
As expected, fatostatin reduced expression of SREBP-1 and SREBP-2, as assessed by IHC (Fig. 8A and 8B , respectively). The albuminuria seen in the Akita mice was augmented by fatostatin (Fig. 8C) . Akita mice had a significant increase in the thickening of the glomerular basement membrane, which was not significantly affected by fatostatin (Fig. 8D) . Renal pathology was assessed by PAS and picrosirius red staining. Akita kidneys demonstrated glomerular hypertrophy (Fig. 9A ) and increased accumulation of collagen (Fig. 9B) . Neither was attenuated by fatostatin.
Discussion
Despite recent advances in the understanding of the pathophysiology of DN, the development of novel therapies has been elusive. SREBP-1 has been suggested to play an important role in the pathogenesis of DN (8, 11, 12, 13) ; however, the therapeutic potential of SREBP inhibition in the treatment of DN has not been previously examined. Our study has shown that fatostatin, an inhibitor of both SREBP-1 and SREBP-2, does not abrogate the development of DN. However, fatostatin promoted renal inflammation in both nondiabetic and diabetic mice and induced glomerular hypertrophy and hyperfiltration in nondiabetic mice. Furthermore, treatment of fatostatin in Akita mice did not attenuate the DN phenotype. These findings do not support a therapeutic role for SREBP inhibition with fatostatin in the treatment or prevention of DN and suggest an important deleterious effect of longer term treatment with fatostatin on kidney function.
Studies have suggested an important pathogenic role for SREBP-1 in renal fibrosis in various models, including DN. Overexpression of SREBP-1a and SREBP-1c led to phenotypic changes reminiscent of DN, including albuminuria, glomerulosclerosis, and upregulation of profibrotic factors (8, 11) . Furthermore, knockout of SREBP-1c attenuated the early development of albuminuria and renal oxidative stress in diabetic mice (11) . Although the Figure 7 . Fatostatin did not inhibit renal oxidative stress or apoptosis. (A) Nox2 mRNA expression was increased in diabetic kidneys (n = 6 per group) as assessed by nanostring. This was not inhibited by fatostatin. (B) Renal oxidative stress was assessed by determining the levels of oxidized DNA in the urine (8-OHdG; n = 5 per group). The increase in diabetes was not inhibited by fatostatin. (C) Renal apoptosis was assessed by cleavage of caspase 3. A trend was seen toward an increase in diabetes, which was further upregulated in diabetic mice treated with fatostatin. *P , 0.05; ¤ P , 0.05 (t test). Con, control; DM, diabetes; Fato, fatostatin. doi: 10.1210/en.2018-00093 https://academic.oup.com/endoconnection between SREBP-2 and DN has not been well studied, a correlation between elevated SERBP-2 expression and DN has also been shown (12, 13) . Furthermore, in models of angiotensin II infusion and unilateral ureteral obstruction, we showed that inhibition of both SREBP-1 and SREBP-2 with fatostatin effectively attenuated renal fibrosis (14, 15) . At the molecular level, we identified an important role for SREBP-1 in the upregulation of, and increased signaling in response to, the important profibrotic cytokine TGF-b1 in mesangial cells (5, 6) . In keeping with this role of SREBP in matrix upregulation, fatostatin protected against increased glomerular basement membrane thickening in our CD1 diabetic model, a characteristic early pathologic change of DN marked by accumulation of matrix components. However, a protective effect of fatostatin in glomerular basement membrane thickening was not seen in the Akita mice, which might indicate that it is unable to reverse matrix accumulation in more advanced DN. Furthermore, neither glomerular nor interstitial fibrosis was attenuated by treatment. We do not as yet have an explanation for these selective effects on the basement membrane. It is possible, however, that fatostatin exerts antifibrotic effects on podocytes and endothelial cells in the diabetic kidney, the two primary contributors to glomerular basement membrane thickening. Lack of attenuation of fibrosis in other regions might have been due to a counterbalancing increase in profibrotic factors such as recruitment of inflammatory cells, as seen in our study. Longer term studies are needed to address whether fatostatin might attenuate later stage DN.
Other key features of DN, including albuminuria, glomerular hypertrophy, and hyperfiltration were not improved by fatostatin. This conflicts with the findings of Ishigaki et al. (11) , who showed attenuation of albuminuria in SREBP-1c knockout mice in early diabetes (8 weeks), although GFR, glomerular hypertrophy, and matrix accumulation were not assessed. The opposing findings in these studies might have resulted from differences in the methods used to inhibit SREBP activity in vivo. Our study used fatostatin, a SCAP inhibitor that decreases the expression and activation of both SREBP-1 and SREBP-2 (21). However, SREBP-2 is upregulated in SREBP-1 knockout mice (43) . It is unknown whether this increased expression of SREBP-2 might be beneficial in DN. SREBP-1 knockout mice were protected from renal oxidative stress (11), but we saw no effect with fatostatin using the same urinary 8-OHdG assay. Further dissection of the individual roles of SREBP-1 and SREBP-2 in DN is thus important. Furthermore, SREBP-1 knockout mice were on a C57BL/6 background, in contrast to the CD1 mice used in our study. It is well known that mouse strains influence the metabolic environment and the expression of nephropathy in diabetes (44, 45) . Finally, it is possible that the deleterious effects of fatostatin might be compound specific. Whether a chemically distinct inhibitor of SREBP-1 and SREBP-2 might more favorably affect DN remains to be investigated. Our study showed that fatostatin increased the GFR and glomerular volume in nondiabetic CD1 mice. The precise nature of this effect remains to be elucidated; however, the associated induction of glomerular hypertrophy suggests that this elevation in GFR might be associated with increased intraglomerular capillary pressures. Hyperfiltration is a well-recognized pathogenic factor in the development of DN, and an increased glomerular volume has been associated with a reduction in kidney function in diabetic patients with both early and advanced DN (46) (47) (48) (49) . Thus, these would be important contributors to the lack of beneficial effect in diabetic mice and deleterious effect in nondiabetic mice. However, in diabetic mice, fatostatin did not further elevate the GFR (CD1 mice) or glomerular hypertrophy (CD1 and Akita mice). This suggests that the pathological effects of fatostatin might be masked by the diabetic phenotype. Further studies are needed of the role of SREBP and the effects of fatostatin on renal vascular reactivity.
Renal inflammation has been strongly implicated in the pathogenesis of DN, with macrophage and CD4+ Tcell recruitment to the kidney suggested to exacerbate profibrotic and proinflammatory responses through secretion of cytokines such as tumor necrosis factor-a and TGF-b (50, 51) . Both SREBP-1 and SREBP-2 have been implicated in mediating inflammation through expression of the key cytokines required for the inflammasome. Mice deficient in SREBP-1a have an impaired innate immune response characterized by decreased lipopolysaccharidesdriven Nlrp1a inflammasome induction, caspase-1 activation, and interleukin-1b production in macrophages (29) . Similarly, antagonism of SREBP-1 and SREBP-2 with 25-hydroxycholesterol led to reduced inflammation by inhibiting interleukin-1b expression (52) . In contrast, mice overexpressing SREBP-2 in endothelial cells showed accelerated development of atherosclerotic plaques by promoting NLRP3 expression and inducing the inflammasome (28) . Our own studies in mice with unilateral ureteral obstruction showed a reduction in inflammation by fatostatin, consistent with a proinflammatory role of SREBP-1/2 (16) .
In contrast to these studies, however, our present results indicate that inhibition of SREBP-1 and SREBP-2 with fatostatin led to increased recruitment of CD3+ T-cells in diabetic and nondiabetic uninephrectomized mice and a nonsignificant elevated recruitment of macrophages. Inflammation was detected primarily around the renal capillaries and in the tubulointerstitium and was notably absent from the glomerulus. Several explanations are possible for these divergent findings. The strain of mice used in studies [CD1 in the present study, C57BL/6 previously (16)] could have influenced the inflammatory response. CD1 mice have been shown to develop more severe neuroinflammation than C57BL/ 6 in response to lipopolysaccharides (53) , hypothesized to be due to a stronger response to granulopoiesisenhancing stimuli compared with inbred strains. The metabolically perturbed environment characteristic of diabetes might also influence the role of SREBPs in inflammation. The elevation in GFR and, potentially, intraglomerular pressure might further promote an inflammatory response (54) .
Finally, divergent responses of different renal cells to fatostatin could be important. In cell culture studies, we found that expression of the cytokine MCP-1, which promotes the recruitment of inflammatory cells (55, 56) , was attenuated in mesangial cells but augmented in tubular cells under both normo-and hyperglycemic conditions. Expression of MCP-1 typically occurs in the renal tubules during DN progression (57). Our results indicate that fatostatin induces renal MCP-1 expression in both diabetic and nondiabetic kidneys, with localization to distal renal tubules. This was associated with a further increase in kidney infiltration by CD3+ T cells and a trend toward increased macrophage infiltration. The important pathogenic role of MCP-1 is supported by the protection of MCP-1 knockout mice against development of early DN (57). We did not find significant upregulation of other inflammatory cytokines, including tumor necrosis factor-a and RANTES, although the latter showed a trend toward increased expression. It is possible that their expression might be upregulated more significantly at an earlier or later time point in the course of DN.
Oxidative stress is a known contributor to inflammation and the stimulation of profibrotic cytokines and ECM proteins in DN (58) . NOX subunits Nox2 and Nox4 are upregulated during the pathogenesis of DN (36) . Overexpression of Nox2 in type 1 diabetic Akita mice led to elevated reactive oxygen species production in the kidney and exacerbation of DN within 8 weeks (59). However, knockout for Nox2 was not protective, although this might be attributed to the compensatory elevation of Nox4 expression in these mice (60) . Wholebody and podocyte-specific Nox4 knockout attenuated albuminuria and glomerulosclerosis and improved renal function in diabetic mice (61, 62) . Our results showed that fatostatin did not attenuate the increased Nox2 transcript expression in diabetic mice but, rather, increased transcript levels in nondiabetic mice without altering Nox4 levels. This correlated with a nonsignificant increase in renal oxidative stress. Although the source of increased Nox2 is likely resident renal cells, a contribution from infiltrating macrophages, which are also increased by fatostatin, could not be excluded (63). Further inquiry into the mechanism underlying increased renal oxidative stress in response to fatostatin is needed.
Apoptosis is a well-known mechanism contributing to the progression of DN (37) . Our data show increased apoptosis in diabetic CD1 mice, with a further increase induced by fatostatin. This is in agreement with our data suggesting that in diabetes, treatment with fatostatin might further potentiate renal damage.
In conclusion, our data have shown that, in contrast to what would be expected from our previous studies of fibrotic renal models and in vitro studies (5-7, 15, 16) , fatostatin did not prevent the development of type 1 DN and induced a maladaptive response in nondiabetic mice. Although the reasons underlying this have not yet been fully elucidated, our data suggest that fatostatin alters renal hemodynamics and that differential effects on different cell types are important. Specifically, fatostatin promoted chemokine expression in renal tubular cells, which is likely an important factor in the observed increased inflammatory response in treated mice. Because the mouse genetic background might also be an important modifier of the response to fatostatin, future studies should determine whether similar effects are seen in other type 1 diabetes models. Finally, because fatostatin inhibits both SREBP-1 and SREBP-2, it will be important to define the functional contribution of each of these isoforms to diabetic kidney disease. This could enable the development of a more specific therapeutic agent that can target the profibrotic actions of SREBP without induction of the adverse effects seen in the present study.
